Healthcare >> CEO Interviews >> November 1, 1999
PAULINE GEE was appointed President and Chief Scientific Officer of
Xenometrix, Inc. in February 1999 and brings to the position a deep
understanding of the technology, hands-on experience in the company's
operations and a fresh approach to financial management of the business.
Dr. Gee joined Xenometrix in January 1994 as Associate Lab Director, and
was promoted quickly to Director of Research and Development in May
1994. She became Vice President of Research and Development in July
1995. Before coming to Xenometrix, Dr. Gee was a research scientist as a
Biochemistry Specialist in the Department of Molecular and Cellular
Biology at the University of California, Berkeley. Her work at Berkeley
culminated in a patented set of bacterial strains that are licensed
exclusively to Xenometrix. These proprietary strains form the basis of
the Ames II family of products and services that measure the mutagenic
potential of compounds offered by Xenometrix. In her position as a
Visiting Scholar in the Department of Biological Sciences at Stanford
University from1987 to 1989, Dr. Gee demonstrated for the first time
that the DNA in differentiated neuronal cells is repaired after damage.
From 1985 to 1987, she served as a Canadian Medical Research Council
Postdoctoral Fellow in the Biochemistry Department at the University of
California, Berkeley. Dr. Gee received graduate training in Neurobiology
and Free Radical Chemistry from Simon Fraser University, BC Canada and
was granted a Ph.D. in 1984 and a B.Sc. in Marine Biology and Human
Physiology in 1978. Dr. Gee is a member of the Scientific Advisory Board
of Biomed Diagnostics. In addition to her scientific activities, Dr. Gee
held office positions in various companies while she was a student and
has participated on the boards of various nonprofit musical
organizations. Profile
Inc., First then tell us what you see as your business and company
today?
Ms. Gee: The company was founded in July of
